ESR1 and breast cancer: FGFR2 activation has been shown to repress the activity of the estrogen receptor (ER) regulon (Campbell T. M. et al., 2016), which has been correlated with poor prognosis in a cohort of ER+ breast cancer patients (Castro et al., 2016).